Eli Lilly Strengthens Position in $150B Obesity Drug Competition Amid Novo and Pfizer Rivalry — Potential Benefits for ETFs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Source: Benzinga
Healthcare ETFs Capitalizing on Obesity Drug Boom: Healthcare ETFs are benefiting from the $150 billion obesity-drug market, with major players like Eli Lilly, Novo Nordisk, and Pfizer competing for market share, leading to increased investor interest in diversified ETFs.
Eli Lilly's Strong Performance: Eli Lilly's stock rose nearly 5% following impressive third-quarter earnings, prompting a raised profit forecast, while its significant presence in major healthcare ETFs like XLV and IHE highlights its dominance in the sector.
Novo Nordisk's Strategic Moves: Novo Nordisk is making headlines with a $6.5 billion counterbid for biotech Metsera, which is developing innovative weight-loss treatments, intensifying competition in the GLP-1 market against Pfizer's earlier bid.
Emergence of Themed ETFs: The Roundhill GLP-1 & Weight Loss ETF offers a focused investment opportunity in companies leading the anti-obesity trend, reflecting the growing interest in specialized funds within the pharmaceutical landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.210
Low
24.00
Averages
28.56
High
35.00
Current: 25.210
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Investigational Drug Fails Key Survival Endpoint
- Trial Results: Pfizer's Sigvotatug vedotin failed to show a statistically significant improvement in overall survival compared to Docetaxel in the Phase 3 SigVie-002 study for advanced non-small cell lung cancer, indicating limitations in the drug's efficacy.
- Patient Group Analysis: Among patients who had received only one prior line of therapy, representing two-thirds of the study population, a numerical trend for overall survival and progression-free survival was observed with Sigvotatug vedotin, suggesting potential value in specific patient groups despite lack of statistical significance.
- Exploratory Analysis Findings: No clear correlation was found between IB6 expression levels and clinical response, which may affect further evaluations of the drug's efficacy, highlighting the need for deeper research to understand its mechanisms.
- Future Research Directions: Pfizer plans to continue evaluating Sigvotatug vedotin in other stages and patient populations, as the current results, while not ideal, still hold scientific value, particularly in early treatment settings when combined with immunotherapy.
See More
Pfizer Reports Phase 3 SigVie-002 Study Results
- Clinical Trial Results: Pfizer's SigVie-002 study evaluated sigvotatug vedotin for treating locally advanced or metastatic non-small cell lung cancer, revealing no statistically significant improvement in overall survival compared to standard treatment docetaxel, although a stronger survival trend was noted in patients who had received only one prior line of therapy.
- Safety Profile: The safety profile of sigvotatug vedotin was manageable and consistent with prior studies, indicating good tolerability for patients during treatment, which bolsters confidence for future clinical applications.
- Future Research Plans: Pfizer intends to submit detailed results from SigVie-002 for presentation at upcoming medical congresses and will continue to explore the combination of sigvotatug vedotin with other immunotherapies, particularly in earlier treatment settings to enhance efficacy.
- Market Outlook: Despite not meeting the overall survival endpoint, Pfizer remains optimistic about the potential of sigvotatug vedotin in earlier treatment stages, aiming to deliver eight potential oncology breakthrough drugs by 2030, further solidifying its leadership in the oncology sector.
See More
Pfizer Faces Setback in Lung Cancer Therapy Trial
- Trial Results Disappoint: Pfizer's antibody-drug conjugate sigvotatug vedotin, introduced through its $43 billion acquisition of Seagen, failed to outperform chemotherapy drug docetaxel in a Phase 3 trial, indicating limitations in treating non-small cell lung cancer.
- Patient Recruitment Details: The trial enrolled 703 patients with non-squamous locally advanced, unresectable, or metastatic non-small cell lung cancer who had undergone at least one line of prior treatment, revealing encouraging trends in a subset of patients who had received only one line of systemic therapy despite overall disappointing results.
- Safety and Tolerability: Pfizer noted that sigvotatug vedotin demonstrated a tolerability profile consistent with previous studies, and although the trial did not meet its primary endpoint, strong efficacy outcomes were observed in second-line patients, suggesting potential in specific patient populations.
- Future Research Directions: Pfizer's Chief Oncology Officer Jeff Legos emphasized that the findings from the SigVie-002 trial validate the company's confidence in other studies, including a late-stage trial testing the drug in combination with Merck's Keytruda, highlighting its significance in future treatments.
See More
Pfizer's Cancer Drug Trial Results Mixed Yet Promising
- Trial Result Analysis: Pfizer's investigational antibody-drug conjugate sigvotatug vedotin failed to demonstrate a statistically significant improvement in overall survival compared to docetaxel in the SigVie-002 study involving 703 previously treated non-small cell lung cancer patients, resulting in the primary endpoint not being met.
- Subgroup Performance: Despite the overall disappointing results, sigvotatug vedotin showed promising signals for overall survival and progression-free survival in a prespecified subgroup of patients who had received only one prior line of therapy, indicating potential efficacy in this specific population.
- Manageable Safety Profile: Pfizer reported that the safety profile of sigvotatug vedotin was consistent with earlier studies and manageable, which provides confidence for its use in historically difficult-to-treat patient populations.
- Future Research Directions: Pfizer plans to present detailed results from the SigVie-002 study at an upcoming medical congress and is conducting ongoing late-stage trials evaluating sigvotatug vedotin in combination with Merck's pembrolizumab, reflecting the company's commitment to advancing cancer treatment options.
See More
Pfizer Slows Acquisition Strategy, Focuses on AI
- Acquisition Strategy Shift: Pfizer's $43 billion acquisition of oncology firm Seagen in 2023 enhanced its cancer drug portfolio; however, CEO Albert Bourla indicated no significant acquisitions are planned in the next two years, focusing instead on leveraging AI to improve operational efficiency.
- AI Transformation Potential: Pfizer aims to execute an AI transformation over the next two years to accelerate new drug development, which could not only enhance long-term growth but also yield greater cost savings and efficiency, thereby improving financial performance.
- Stock Performance and Market Opportunity: With a 35% decline in stock price over the past five years, Pfizer is working to enhance operations through AI; if successful, this could attract renewed investor interest despite its currently low valuation.
- High Dividend Appeal: Offering a dividend yield of approximately 6.8%, Pfizer provides a good margin of safety amid market uncertainties, and its low valuation relative to future earnings makes it an attractive option for investors seeking bargains.
See More
Pfizer Faces Patent Expiration Challenges
- Significant Stock Decline: Pfizer's stock has plummeted over 50% since its late 2021 peak, resulting in a dividend yield of 6.8%, significantly above the pharmaceutical average of 1.6%, indicating investor concerns about the company's future.
- Patent Expiration Pressure: The company is facing revenue declines due to patent expirations on several drugs in the coming years, which is typical in the industry; however, the lack of new drug replacements exacerbates the situation.
- Long-standing Company: With over a century of history, Pfizer has successfully navigated through tough times before, and while it faces current challenges, its established reputation and experience in the healthcare sector may help it weather this storm.
- Long-term Investment Opportunity: Although there may be short-term pressure on dividends, Pfizer's long-term growth potential remains, and investors looking at a decade-long horizon might find that buying Pfizer stock could lead to significant wealth accumulation.
See More
Pfizer's Investigational Drug Fails Key Survival Endpoint
- Trial Results: Pfizer's Sigvotatug vedotin failed to show a statistically significant improvement in overall survival compared to Docetaxel in the Phase 3 SigVie-002 study for advanced non-small cell lung cancer, indicating limitations in the drug's efficacy.
- Patient Group Analysis: Among patients who had received only one prior line of therapy, representing two-thirds of the study population, a numerical trend for overall survival and progression-free survival was observed with Sigvotatug vedotin, suggesting potential value in specific patient groups despite lack of statistical significance.
- Exploratory Analysis Findings: No clear correlation was found between IB6 expression levels and clinical response, which may affect further evaluations of the drug's efficacy, highlighting the need for deeper research to understand its mechanisms.
- Future Research Directions: Pfizer plans to continue evaluating Sigvotatug vedotin in other stages and patient populations, as the current results, while not ideal, still hold scientific value, particularly in early treatment settings when combined with immunotherapy.
See More
Pfizer Reports Phase 3 SigVie-002 Study Results
- Clinical Trial Results: Pfizer's SigVie-002 study evaluated sigvotatug vedotin for treating locally advanced or metastatic non-small cell lung cancer, revealing no statistically significant improvement in overall survival compared to standard treatment docetaxel, although a stronger survival trend was noted in patients who had received only one prior line of therapy.
- Safety Profile: The safety profile of sigvotatug vedotin was manageable and consistent with prior studies, indicating good tolerability for patients during treatment, which bolsters confidence for future clinical applications.
- Future Research Plans: Pfizer intends to submit detailed results from SigVie-002 for presentation at upcoming medical congresses and will continue to explore the combination of sigvotatug vedotin with other immunotherapies, particularly in earlier treatment settings to enhance efficacy.
- Market Outlook: Despite not meeting the overall survival endpoint, Pfizer remains optimistic about the potential of sigvotatug vedotin in earlier treatment stages, aiming to deliver eight potential oncology breakthrough drugs by 2030, further solidifying its leadership in the oncology sector.
See More
Pfizer Faces Setback in Lung Cancer Therapy Trial
- Trial Results Disappoint: Pfizer's antibody-drug conjugate sigvotatug vedotin, introduced through its $43 billion acquisition of Seagen, failed to outperform chemotherapy drug docetaxel in a Phase 3 trial, indicating limitations in treating non-small cell lung cancer.
- Patient Recruitment Details: The trial enrolled 703 patients with non-squamous locally advanced, unresectable, or metastatic non-small cell lung cancer who had undergone at least one line of prior treatment, revealing encouraging trends in a subset of patients who had received only one line of systemic therapy despite overall disappointing results.
- Safety and Tolerability: Pfizer noted that sigvotatug vedotin demonstrated a tolerability profile consistent with previous studies, and although the trial did not meet its primary endpoint, strong efficacy outcomes were observed in second-line patients, suggesting potential in specific patient populations.
- Future Research Directions: Pfizer's Chief Oncology Officer Jeff Legos emphasized that the findings from the SigVie-002 trial validate the company's confidence in other studies, including a late-stage trial testing the drug in combination with Merck's Keytruda, highlighting its significance in future treatments.
See More
Pfizer's Cancer Drug Trial Results Mixed Yet Promising
- Trial Result Analysis: Pfizer's investigational antibody-drug conjugate sigvotatug vedotin failed to demonstrate a statistically significant improvement in overall survival compared to docetaxel in the SigVie-002 study involving 703 previously treated non-small cell lung cancer patients, resulting in the primary endpoint not being met.
- Subgroup Performance: Despite the overall disappointing results, sigvotatug vedotin showed promising signals for overall survival and progression-free survival in a prespecified subgroup of patients who had received only one prior line of therapy, indicating potential efficacy in this specific population.
- Manageable Safety Profile: Pfizer reported that the safety profile of sigvotatug vedotin was consistent with earlier studies and manageable, which provides confidence for its use in historically difficult-to-treat patient populations.
- Future Research Directions: Pfizer plans to present detailed results from the SigVie-002 study at an upcoming medical congress and is conducting ongoing late-stage trials evaluating sigvotatug vedotin in combination with Merck's pembrolizumab, reflecting the company's commitment to advancing cancer treatment options.
See More
Pfizer Slows Acquisition Strategy, Focuses on AI
- Acquisition Strategy Shift: Pfizer's $43 billion acquisition of oncology firm Seagen in 2023 enhanced its cancer drug portfolio; however, CEO Albert Bourla indicated no significant acquisitions are planned in the next two years, focusing instead on leveraging AI to improve operational efficiency.
- AI Transformation Potential: Pfizer aims to execute an AI transformation over the next two years to accelerate new drug development, which could not only enhance long-term growth but also yield greater cost savings and efficiency, thereby improving financial performance.
- Stock Performance and Market Opportunity: With a 35% decline in stock price over the past five years, Pfizer is working to enhance operations through AI; if successful, this could attract renewed investor interest despite its currently low valuation.
- High Dividend Appeal: Offering a dividend yield of approximately 6.8%, Pfizer provides a good margin of safety amid market uncertainties, and its low valuation relative to future earnings makes it an attractive option for investors seeking bargains.
See More
Pfizer Faces Patent Expiration Challenges
- Significant Stock Decline: Pfizer's stock has plummeted over 50% since its late 2021 peak, resulting in a dividend yield of 6.8%, significantly above the pharmaceutical average of 1.6%, indicating investor concerns about the company's future.
- Patent Expiration Pressure: The company is facing revenue declines due to patent expirations on several drugs in the coming years, which is typical in the industry; however, the lack of new drug replacements exacerbates the situation.
- Long-standing Company: With over a century of history, Pfizer has successfully navigated through tough times before, and while it faces current challenges, its established reputation and experience in the healthcare sector may help it weather this storm.
- Long-term Investment Opportunity: Although there may be short-term pressure on dividends, Pfizer's long-term growth potential remains, and investors looking at a decade-long horizon might find that buying Pfizer stock could lead to significant wealth accumulation.
See More
